<DOC>
	<DOCNO>NCT00244712</DOCNO>
	<brief_summary>This study design test safety effectiveness EPZICOM ( abacavir/lamivudine ) TRUVADA ( emtricitabine/tenofovir ) treatment HIV infection use combination KALETRA ( lopinavir/ritonavir ) 96 week</brief_summary>
	<brief_title>Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Inclusion criterion : Males female least 18 year old . ( A female eligible enter participate study : non childbearing potential , child bear potential negative pregnancy test agree approve contraception method , agreement complete abstinence . ) Subject antiretroviralnaïve ( define ≤14 day prior therapy NRTI prior therapy either PI NNRTI ) . Subject plasma HIV1 RNA ≥ 1,000 copies/mL screening . Subject willing able understand provide write informed consent prior participation study . Exclusion criterion : Subject active acute CDC Clinical Category C event ( exclusive cutaneous Kaposi 's sarcoma ) screening . Treatment acute event must complete least 30 day prior screen . Subject enrol one investigational drug protocol , may impact HIV1 RNA suppression . Subject , opinion investigator , unable complete 96week dose period protocol evaluation assessment . Subject either pregnant breastfeeding . Subject ongoing clinically relevant pancreatitis clinically relevant hepatitis screening . Subject suffers serious medical condition , cirrhosis , diabetes , congestive heart failure , cardiomyopathy cardiac dysfunction , opinion investigator would compromise safety subject . Subject preexist mental , physical , substance abuse disorder , opinion investigator , may interfere subject 's ability comply dose schedule protocol evaluation assessment . Subject history inflammatory bowel disease malignancy , intestinal ischemia , malabsorption , gastrointestinal dysfunction may interfere drug absorption render subject unable take oral medication . Subject acute laboratory abnormality screening , , opinion investigator , preclude subject 's participation study investigational compound . Any grade 4 laboratory abnormality exclude subject study participation . Subject estimate creatinine clearance &lt; 50 mL/min via CockroftGault method . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) . Subject require treatment radiation therapy cytotoxic chemotherapeutic agent within 28 day prior screen , anticipated need agent within study period . Subject require treatment immunomodulating agent ( systemic corticosteroid , interleukin , vaccine , interferon ) within 28 day prior Screen , subject receive HIV1 immunotherapeutic vaccine within 90 day prior Screen . Asthmatic subject use inhaled corticosteroid eligible enrollment . Subject require treatment foscarnet , hydroxyurea agent document activity HIV1 vitro within 28 day study administration . Subjects require treatment prohibit medication within 28 day commencement investigational product , anticipate need study . Subject history allergy study drug excipients therein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HEAT</keyword>
	<keyword>Antiretroviral-naive</keyword>
	<keyword>HIV</keyword>
	<keyword>EPZICOM</keyword>
	<keyword>TRUVADA</keyword>
	<keyword>KALETRA</keyword>
	<keyword>once-daily</keyword>
</DOC>